A Pregnant Woman with Type 2 Diabetes Unintentionally Exposed to Metformin and Voglibose until the Second Trimester of Pregnancy: A Case Report.
10.4093/jkd.2016.17.4.277
- Author:
Yeo Un KIM
1
;
Jae Hoon KWAK
;
Se Hwan YEO
;
Seong Su MOON
;
Young Sil LEE
Author Information
1. Department of Internal Medicine, Dongguk University College of Medicine, Gyeongju, Korea. ysbae28@hanmail.net
- Publication Type:Randomized Controlled Trial ; Case Report
- Keywords:
Diabetes mellitus type 2;
Hypoglycemic agents;
Pregnancy
- MeSH:
Bisoprolol;
Diabetes, Gestational;
Female;
Glyburide;
Humans;
Hypoglycemic Agents;
Insulin;
Metformin*;
Organogenesis;
Pregnancy;
Pregnancy Trimester, Second*;
Pregnancy*;
Pregnant Women*
- From:Journal of Korean Diabetes
2016;17(4):277-281
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Use of oral hypoglycemic agents during pregnant women with type 2 diabetes is controversial due to safety issues. Recently, randomized controlled trials support short-term safety of glyburide and metformin for the treatment of gestational diabetes mellitus. However, long-term safety data are not available. Moreover, use of oral hypoglycemic agents, except for metformin and glyburide, during pregnancy were limited to a few case reports. We report the case of a pregnant woman with type 2 diabetes unintentionally exposed to metformin and voglibose in addition to lercanidipine and bisoprolol during fetal organogenesis. The patient was continuously exposed to oral agents because we were not aware of her pregnancy until 22 weeks of gestation. After pregnancy was confirmed, we replaced oral hypoglycemic agents with insulin and discontinue betablockers. Delivery occurred without maternal or fetal complications.
